ANGN News and Press, Angion Biomedica Corp. From 02/07/22

Angion Biomedica Corp was the fifth worst IPO of 2021, down over 80% as its lead candidate failed one Phase 3 and two Phase 2 trials. The company recently announced a pivot to its other clinical asset – a potential therapy for fibrotic diseases of the kidney and lungs. Trad...

-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases -- Angion will end 2021 with approximately $88.8 million in cash and cash equivalents UNIONDALE, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a...

Gainers: American Virtual Cloud Technologies (NASDAQ:AVCT) +50%. Petros Pharmaceuticals (NASDAQ:PTPI) +28%. BioLineRx (NASDAQ:BLRX) +24%. SigmaTron (NASDAQ:SGMA) +20%. Oracle (NYSE:ORCL) +15%. Sprinklr (NYSE:CXM) +15%. Nam Tai Property (NYSE:NTP) +14%. Vasta (NASDAQ:VSTA) +15%. Bottomline Tec...

Gainers: Petros Pharmaceuticals (NASDAQ:PTPI) +37%, Biofrontera BFRI +20%, ABVC BioPharma (NASDAQ:ABVC) +12%, Halozyme Therapeutics (NASDAQ:HALO) +11%, Context Therapeutics CNTX +9%. Losers: Angion Biomedica (NASDAQ:ANGN) -22%, Ensysce Biosciences ...

Everbridge (NASDAQ:EVBG) -36% on CEO resignation, downgrade Code Chain New Continent (NASDAQ:CCNC) -33% on proposed common stock and warrants offering. Angion Biomedica (NASDAQ:ANGN) -21% after mid-stage acute kidney injury drug misses primary endpoint American O...

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced re...

Shares of Angion Biomedica (NASDAQ:ANGN) have tumbled 17% after it reported that a phase 2 trial of its cardiac-surgery associated acute kidney injury drug ANG-3777 missed its primary endpoint. That endpoint was percentage increase in serum creatinine based upon the area under the c...

-- Angion to host a conference call today at 4:30 p.m. EST UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of Angion’s ANG-3...

Angion Biomedica (NASDAQ:ANGN): Q3 GAAP EPS of -$0.53 beats by $0.19. Revenue of $1.46M (+75.9% Y/Y) beats by $0.4M. Press Release For further details see: Angion Biomedica EPS beats by $0.19, beats on revenue

UNIONDALE, N.Y., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provi...